01—Abstract
Summary
Summary of the 8-K filed May 19, 2026. Cited figures are marked; the original filing is the authoritative source.
Amgen (AMGN) announced in an 8-K filed May 19, 2026 that CFO Peter H.
Griffith will retire from his Executive Vice President and Chief Financial Officer role effective August 31, 2026, after serving in the role since 2020. He will remain employed as a non-executive Executive Vice President through January 31, 2027 to support a transition, and he is retirement-eligible under company plans, so he will receive standard retirement benefits upon departure. Thomas Dittrich, 62, has been named his successor.
He joins as a non-executive Executive Vice President on July 1, 2026 and becomes Executive Vice President and CFO effective September 1, 2026, reporting to Chairman and CEO Robert A. Bradway. He previously held senior finance roles at Amgen (including VP Finance and Chief Accounting Officer) and most recently served as CFO of Galderma Group AG, with prior CFO roles at Shire and Sulzer.
His service at Galderma is expected to end June 30, 2026. Investors should note that the disclosed compensation package is substantial and front-loaded with make-whole awards designed to offset forfeited equity at his current employer. The transition appears planned and overlapping, with a two-month handover period and a retiring CFO available through January 2027, which reduces near-term execution risk.
The filing does not indicate any change to Amgen's financial guidance, operations, or pipeline. The main items to monitor are Dittrich's relocation from Switzerland to California, the retention clawback terms, and whether the new CFO sets different capital allocation or reporting priorities.
02—Key points
Key Highlights
- CFO Peter Griffith retires as EVP and CFO effective August 31, 2026; he stays on as a non-executive EVP through January 31, 2027 to support the transition.
- Thomas Dittrich, former CFO of Galderma, joins as EVP on July 1, 2026 and becomes EVP and CFO on September 1, 2026, reporting to CEO Robert Bradway.
- Dittrich's base salary is CHF 1,070,000 with a 100% target bonus under the Global Management Incentive Plan.
- Annual long-term equity target is CHF 4.5 million, split across options, RSUs, and 2026–2028 performance units, plus make-whole awards including a CHF 4.7 million RSU grant and a CHF 4.0 million cash bonus.
- A CHF 5.8 million two-year retention bonus is repayable pro-rata if Dittrich resigns or is terminated for certain misconduct within two years.
- Severance protection is two times salary plus target bonus if terminated without cause within two years of hire; a CHF 250,000 relocation allowance is also provided.
- The filing reports no changes to financial guidance or operations; the press release describes the change as a planned, seamless transition.
03—Questions
Frequently Asked Questions
Why is Peter Griffith leaving as CFO?
The filing states that Griffith is retiring and is retirement-eligible under company plans. He will receive standard retirement benefits upon his departure in January 2027.
Who is replacing Peter Griffith and what is his background?
Thomas Dittrich, 62, will become EVP and CFO on September 1, 2026. He most recently served as CFO of Galderma Group AG (since 2019), previously was CFO of Shire and Sulzer, and held senior finance roles at Amgen from 2006 to 2014.
How large is Dittrich's compensation package?
Base salary is CHF 1.07 million with a 100% target bonus, and annual long-term incentives have a target value of CHF 4.5 million. One-time make-whole payments include a CHF 4.7 million RSU award, a CHF 4.0 million cash bonus, and a CHF 5.8 million retention bonus, plus a CHF 250,000 relocation allowance.
Does the retention bonus create any obligation if Dittrich leaves early?
Yes. The CHF 5.8 million retention bonus is repayable on a pro-rata basis by days served if Dittrich resigns, or is terminated for certain misconduct, within two years of his hire date.
Does this CFO change affect Amgen's financial outlook?
The 8-K does not discuss changes to financial guidance, operations, or products. The press release characterizes the change as a planned transition, with Griffith remaining through January 2027 to support continuity.
04—Continue